Safety of baricitinib in East Asian patients with moderate‐to‐severe active rheumatoid arthritis: An integrated analysis from clinical trials

Aim We evaluated the safety of baricitinib in an East Asian (EA) patient population with moderate‐to‐severely active rheumatoid arthritis (RA), through an integrated sub‐analysis of data from the overall baricitinib RA clinical program. Methods Data from EA patients who received any dose of baricitinib from five completed studies (1 Phase 2, 4 Phase 3) and an ongoing long‐term extension study were pooled up to 1 September, 2016....